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Abstract: Individualized parenteral nutrition is the most specialized type of nutritional support in the
hospital setting. The composition and prescribing patterns for parenteral nutrition have evolved due
to new emerging scientific evidence. In the last few years, there has been a tendency to increase the
nitrogen and lipid content and decrease the carbohydrate content. To assess the prescribing pattern in
a tertiary referral hospital in Spain, the nutritional composition of individualized parenteral nutrition
was evaluated retrospectively from January to December of 2016. A total of 3029 parenteral nutrition
units were analysed, corresponding to 257 hospitalized adult patients. Medical specialists in General
Surgery and Haematology were the most common petitioners. The three most frequently prescribed
parenteral nutrition formulae contained 13.4 (28.8%), 15.7 (19.54%) and 17.9 (17.79%) g of nitrogen.
The quantity of carbohydrates and lipids showed a mean non-protein calories-to-nitrogen ratio of
approximately 78:1 and a carbohydrate-to-lipid ratio that was near 50:50 in most cases. These results
suggest a trend towards the administration of parenteral nutrition with a high content of nitrogen
and smaller proportion of the non-protein components.
Keywords: parenteral nutrition; nutritional composition; nitrogen content; lipid emulsion;
prescribing patterns; tertiary hospital; acute disease
1. Introduction
Individualized parenteral nutrition (PN) is the most specialized type of nutritional treatment in
inpatient settings and is received by approximately 2–3% of patients [1].
Since the discovery of circulation by William Harvey in 1628, many scientists have tried to
administer nutrients through the parenteral route with favourable and unfavourable results. Of note
are the contributions of Stanley Dudrick, who first administered intravenous nutrients directly into
the central venous circulation. He produced satisfactory results by first raising beagle puppies fed
only this way and later from the first infant fed with only an intravenous nutrient supply in 1967 [2].
Thus, the evolution of science allowed the improvement of this nutritional support, especially in the
second half of the 20th century. In the last few years, efforts have been focused on PN solutions and
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the amounts of macro- and micronutrients added to the bag. In that sense, the increase in the protein
content of PN and the evolution of the lipid emulsions has been highlighted.
Regarding the protein component, a considerable amount of literature has emerged that
recommends increasing the amount of nitrogen in the PN bags, which is more important than the total
calorie count in some cases [3].
The first available intravenous lipid emulsion (IVLE) was developed by Schubert and Wretlind in
1961 and consisted of soybean oil stabilized by egg phosphatides [4]. The soybean lipid emulsions
were characterized by a high content of omega-6 polyunsaturated fatty acids (PUFA) [5]. Despite being
reasonably safe, the potential pro-inflammatory and hepatotoxic effects of soybean emulsions were
well known [6] and they were reconfigured for the latest IVLE generations. These later generations
incorporate alternative lipids, such as olive oil or fish oil, to create olive/soy-based formulations.
The recent IVLEs use a combination of many lipids (soy/medium chain triglycerides/olive/fish
oil), which have anti-inflammatory and immune modulating effects and little hepatotoxicity [7].
SMOFlipid® (Fresenius Kabi®), containing soy (30%), medium-chain triglycerides (MCT) (30%),
olive oil (25%) and fish oil (15%), belongs to the group of IVLEs with the above-mentioned
beneficial properties.
These two alterations, which are namely the increase in the protein component and the latest IVLE,
have changed the macronutrient profile of the PN bags over the last years, leading to the incorporation
of more lipids and nitrogen and fewer carbohydrates.
However, data about real clinical practice are scarce, especially data not from Intensive Care Units
(ICUs). To assess whether our prescribing patterns comply with the literature recommendations and to
review our own protocols, we have studied the composition of all individualized PN bags prescribed
by our Nutrition Support Team for adults not staying in the ICU during the year of 2016.
2. Materials and Methods
A retrospective descriptive study was conducted. Records were collected for the nutritional
composition of all individualized PN units, which were prescribed by physicians of the Nutrition
Unit of La Paz University Hospital, Madrid, Spain, and aseptically manufactured in the pharmacy of
the same hospital as all-in-one solutions between January and December of 2016. The following data
were collected: macronutrient profile (nitrogen, carbohydrates, lipids (g)), type of intravenous lipid
emulsion, micronutrient profile (sodium, potassium, chloride, calcium, magnesium and phosphorus
(mEq/L)), volume (mL) and total calories (kcal). The nonprotein calories-to-nitrogen ratio (NPC:N) and
carbohydrate-to-lipid (CH/lipid) ratio were also calculated. Other general variables were collected,
including: number of PN units prescribed per patient and the medical speciality of the petitioners.
Commercial multi-chamber PN units, paediatric PN (patients <18 years old) units and PN units from
ICU stays were not included.
The physician prescribers have several individualized standard formulae available that were
designed together with the hospital pharmacists, which can fit many of the possible patient
macronutrient profiles. These formulae consider a range of weights and degrees of metabolic stress
and have a fixed composition. If they fit the patient’s calculated requirements, the pharmacists use this
particular formula for the PN unit. If the prescribers ask for any modification to the profile, it is made.
All analyses were performed using SPSS v.17.0 software (SPSS Inc., Chicago, IL, USA).
Significance was set at α = 0.05. Descriptive statistics were calculated (mean and standard deviation
(SD) for quantitative variables and percentages for qualitative variables).
3. Results
A total of 3029 individualized parenteral nutrition units, corresponding to 257 patients,
were analysed. Each patient received an average of 11.7 PN units during his/her hospital stay.
Figure 1 shows the number of PN units distributed by each clinical requesting service.
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Carbohydrate (dextrose), lipid and macronutrient ratios are described using the amount of N
as a reference (Table 2). In the PN group containing 13.4 g of N, the most common macronutrient
profile contained 140 g of carbohydrates with 55 g of lipids (551 units, 18.19%), while the second most
common macronutrient profile included 170 g of carbohydrates with 70 g of lipids. Other carbohydrate
quantities (120, 150, 160 or 165 g) were added at smaller proportions (<10%). On the other hand, in the
PN group containing 15.7 g of N, the most common quantities of carbohydrates were 160 and 200 g
with 60 and 80 g of lipids, respectively. Finally, the amount of carbohydrates that was most commonly
added to PN containing 17.9 g of N was 180 g with 70 g of lipids, while the second most common
addition was 225 g of carbohydrates with 90 g of lipids. The total calorie contents are also shown in
Table 2.
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Regarding the lipid profile, all the parenteral nutrition units prescribed in the La Paz University
Hospital included SMOFlipid®, except for 13 PN units (corresponding to 6 patients), which did not
contain any type of IVLE.
Table 2. Carbohydrate, lipid and macronutrient ratios along with total calories in prescribed PN
formulae using nitrogen content as a reference.
Nitrogen
(g)
Carbohydrates
(g)
Lipids
(g)
CH/Lipid
Ratio NPC:N
PN (Units
(%))
Total Energy
Intake (kcal)
13.4 140 55 53.08/46.92 78:1 505 (16.67) 1447.49
13.4 170 70 51.90/48.1 97:1 215 (7.09) 1716.01
15.7 160 60 54.23/45.77 75:1 354 (11.68) 1632.51
15.7 200 80 52.63/47.37 96:1 195 (6.43) 1992.51
17.9 180 70 53.33/46.67 75:1 379 (12.51) 1867.5
17.9 225 90 52.63/47.37 95:1 106 (3.49) 2247.5
CH: Carbohydrate. NPC:N: Nonprotein calories-to- nitrogen ratio. PN: Parenteral Nutrition.
3.2. Micronutrient Composition and Volume
The micronutrient profile is detailed in Table 3 and volume in Table 4. All PN formulae contained
vitamins and trace elements (data not shown).
Table 3. Micronutrient profile in relation to nitrogen content (mean ± SD).
N (g) Na (mEq) K (mEq) Cl (mEq) Mg (mEq) Ca (mEq) P (mEq)
13.4 97.01 ± 25.19 67.97 ± 26.66 80.16 ± 24.21 15.13 ± 3.66 13.99 ± 4.03 22.52 ± 8.24
15.7 84.84 ± 34.13 72.38 ± 25.09 80.01 ± 25.18 14.74 ± 4.39 14.35 ± 4.01 22.76 ± 7.94
17.9 102.87 ± 17.24 71.31 ± 19.29 84.77 ± 14.80 14.70 ± 4.30 14.96 ± 2.08 23.45 ± 8.55
Table 4. Total volume of parenteral nutrition in relation to nitrogen content (mean ± SD).
N (g) Volume (mL)
13.4 1891.92 ± 251.71
15.7 2109.71 ± 297.89
17.9 2443.91 ± 392.19
4. Discussion
The quality and quantity of the nutrients in parenteral nutrition formulae have been changing
in recent years due to increased knowledge and changes in the recommendations made by scientific
organizations. For example, we have increased the amount of nitrogen in the parenteral nutrition
formulae and drastically decreased the total calorie content in the last few years.
New data have emerged, particularly regarding critically ill patients, which supports the need
for increasing the amount of nitrogen in PN formulae. In 2017, the International Protein Summit
recommended a minimum of 1.2 g/kg/day and up to 2.0–2.5 g/kg/day of protein for critically ill
patients admitted to the ICU [8]. These protein contents are similar to those suggested in 2016 by the
American Society for Parenteral and Enteral Nutrition (ASPEN) guidelines [9] as they observed that
the protein requirements may be in the range of 1.2–2.0 g/kg of actual body weight/day, thus driving
their recommendation of high protein content. However, the 2009 European Society for Clinical
Nutrition and Metabolism (ESPEN) guidelines recommended an amino acid supply of approximately
1.3–1.5 g/kg of ideal body weight/day [10]. Singer et al. [3] also recommended a high protein intake
(1.5 g/kg/day) during the early phase of the ICU stay and they highlighted the importance of the
nitrogen component regardless of the simultaneous calorie intake.
Nutrients 2018, 10, 1079 5 of 9
Data about the non-critically ill patient (outside of guidelines) are scarce. The ESPEN guidelines
advised a dosage that depends on the aetiology of the illness. This can range from a minimum
of 1.0 g/kg/day, such as for medical inpatients with multiple comorbidities [11], to a maximum
of 2.0 g/kg/day in others, such as some oncology patients [12,13]. The extent of the malnutrition
or the severity of the protein depletion will also influence the protein requirements. For example,
the ESPEN expert group recommendations for action against cancer-related malnutrition [14] suggest
that more than 1.2–1.5 g/kg/day of protein may be needed in severely depleted patients. Additionally,
for protein-energy wasting during chronic renal failure, adapting the dietary protein intake target is
recommended [15]. A study showing the trend of increasing nitrogen content and reducing NPC:N
ratio inside and outside of the ICU was performed by Villalobos-Gámez et al. [16]. They evaluated the
nitrogen content of 1604 PN units prescribed in the hospitalization ward and in the ICU of a Spanish
tertiary level hospital during a 4-year period. The mean nitrogen content increased from 14.00 ± 3.28
in the first year to 15.05 ± 4.24 in the last one (g of nitrogen, mean ± SD), while there was a decrease in
the NPC:N ratio from 111.6± 22.2 to 101.8± 25.4. For the last year of their study, they also reported the
following nitrogen contents (g of nitrogen, mean ± SD) and the NPC:N ratios for the hospitalization
ward, the ICU and the subset of ICU patients with renal replacement therapy: 13.56 ± 3.13, 15.87 ± 4.19
and 17.60 ± 4.28, respectively for nitrogen content and 112.2 ± 20.1, 97.3 ± 22.6 and 89.68 ± 18.4,
respectively for NPC:N ratio. The mean amount of nitrogen in the hospitalization ward is very similar
to our most commonly prescribed amount of nitrogen, but our NPC:N ratios are more similar to those
prescribed in the ICU. This is because many of our patients are in an acute phase of their illness, such as
patients with haematological tumours who require a stem cell transplantation or those who are in the
postoperative phase of major surgery. All of these patients require more nitrogen and less glucose
and lipids, resulting in a lower NPC:N ratio. The distribution between the protein and non-protein
components is quantitively described to create the PN and confer the desired degree of metabolic stress
to the formula, considering that both protein and non-protein calories are oxidized as a calorie source.
SMOFlipid® was first approved in Europe in February 2004 and for the USA in July 2016. Since
it became available, many studies have assessed its properties and compared it with other IVLEs.
In one study comparing ClinOleic® (MCT/long chain triglycerides (LCT) and oleic acid, Baxter®)) and
SMOFlipid® in 154 surgical patients who needed PN for at least 7 days, no significant differences were
found for the clinical parameters (days on PN, length of stay, infection and mortality) or the biochemical
parameters (lipid profile, hepatic profile, glucose, albumin, lymphocytes) between the two IVLEs.
The authors attribute the lack of differences to the similar fatty acid compositions of both emulsions
(having less PUFA than their previous soy-based lipid emulsion) and the presence of α-tocopherol
in both solutions. The lipid content of their PN comprised 40% of the non-protein calories [17].
In 2013, Klek et al. [18] conducted a double-blind, multicentre study on 73 adults with stable intestinal
failure who were randomized to receive PN with SMOFlipid® or PN with Intralipid® (soybean oil
emulsion, Fresenius Kabi®) for 4 weeks. These PN contained a lipid dosage of 1–2 g/kg/day. In the 4th
week, they found that the mean concentrations of alanine transaminase (ALT), aspartate transaminase
(AST) and total bilirubin were significantly lower in the SMOFlipid® group (p = 0.049, 0.027 and
0.043, respectively). They did not find differences in serum triglycerides, haematological parameters,
International Normalized Ratio (INR), or cytokine markers of inflammation, such as Interleukin-6
(IL-6), Tumoral Necrosis Factors-RII (STNF-RII) and C Reactive Protein (CRP). Tien et al. [19] evaluated
the safety and efficiency of SMOFlipid® compared to other parenteral lipid emulsions in postoperative
patients in a meta-analysis of randomized controlled trials, which included 6 trials with a total of
306 patients. Other parenteral lipid emulsions were Lipoven® (soybean based, Fresenius Kabi®),
ClinOleic® (Baxter®) and MCT/LCT® (MCT/LCT, B.Braun®). The duration of PN treatment was
4–6 days. Compared to Lipoven® and ClinOleic®, SMOFlipid® decreased serum liver enzymes and
unlike Lipoven®, it decreased low-density lipoprotein triglycerides and CRP levels. They found no
differences between SMOFlipid® and MCT/LCT®. The studies evaluating SMOFlipid® and Lipoven®
only provide moderate quality evidence.
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Our hospital first introduced SMOFlipid® in January 2005 and based on the already mentioned
beneficial properties, the satisfactory evolution of our patients and the current guidelines, we were able
to increase the proportion of lipids in the non-protein component and decrease the amount of glucose.
Therefore, our results show that most of our PN have a CH:lipid ratio that is close to 50:50. With this
ratio, the patient benefits from lowered glucose and avoids unnecessary overload. On the other hand,
as the amount of nitrogen has been calculated based on the patient’s weight and degree of metabolic
stress, the lipid composition of the PN does not influence the protein component. These results comply
with the 2009 ESPEN guidelines, which recommend the use of formulae with higher lipid contents
(up to 50% of the total energy) in geriatric patients [20]. For patients with alcoholic steatohepatitis and
liver cirrhosis, they proposed that the glucose amount should cover 50–60% of the non-protein energy
requirements with 40–50% of lipids (with IVLE containing less N-6 PUFA than the traditional pure
soybean oil emulsions) [21]. For non-surgical oncology patients, they suggest using a higher percentage
of lipids, such as an amount of lipids that will cover 50% of the non-protein energy requirements [13].
On the other hand, in 2009, the ESPEN guidelines in Gastroenterology recommended that 2/3 of the
calorie requirements should be derived from glucose and 1/3 from a lipid emulsion [22]. For acute
pancreatitis, glucose should represent between 50% and 70% of total calories, while the infusion
should be temporarily discontinued if persistent (>72 h) hypertriglyceridemia occurs (>12 mmol/L =
1050 mg/dL) [23]. Finally, for surgical patients, they mentioned a tendency to increase the CH:lipid
calorie ratio of the non-protein calories from 50:50 to 60:40 or even 70:30 due to the problems with
hyperlipidaemia and fatty liver, which is a grade C recommendation [24]. However, in cases of liver
damage or persistent elevated liver function tests, we also adapted our PN formulae in order to
adjust the recommendations to fit with our clinical practice. This involves changing the amount of
glucose (always ≤5 g/kg/day) and lipids (≤1 g/kg/day) and even administering the PN bag for
approximately 12 h. Similarly, these actions are also recommended in cases of liver damage that is
associated with home PN [25] but these data have not been analysed. In the more recent ESPEN
guidelines [5,11,26,27], no specific data about the CH:lipid ratio are provided, except in the case of
Cancer Patients Guidelines, where they strongly recommend increasing the ratio of energy from fat to
energy from carbohydrates in cancer patients with insulin resistance that have been losing weight [12].
In a recent survey [28] by the ASPEN PN Safety Committee that asked clinicians about IVLE
prescription, preparation and administration for adult patients, 42.1% of clinicians prescribed a
compounded dextrose/amino acid solution (2-in-1); 41.9% prescribed a compounded total nutrient
admixture (3-in-1); 1.7% prescribed a commercial multi-chamber bag with injectable lipid emulsion
(ILE) in the bag; 12% prescribed a commercial multi-chamber bag without ILE in the bag; and 2.3%
prescribed a commercial multi-chamber bag without ILE in the bag, with the pharmacy adding ILE
to the bag. ILE administration as a separate infusion was noted by 43.1% of the surveyed clinicians.
This differs from our current clinical practice, where almost 99% of patients receive lipids in their
individualised PN made by the pharmacy service (according to our requests) as an all-in-one solution.
Only 13 PN nutrition units were formulated without lipids, which reflects the vagaries and need for
clinical judgement in clinical practice. Overall, some reasons for the omission of lipids in our clinical
practice include moderate-to-severe hepatopathy, such as severe hepatic graft-versus-host disease,
sinusoidal obstruction syndrome in stem cell transplantation or severe hypertriglyceridemia.
The micronutrient profiles and volumes show that a commercial multi-chamber PN would
not have fulfilled the electrolyte and fluid requirements of our patients, because the average fixed
electrolyte profile provides fewer electrolytes, particularly sodium, potassium and chloride, in more
volume. Beattie C et al. [29] obtained similar results when they compared 97 individualised PN
bags with premixed multi-chamber ones as they observed that the sodium, potassium and chloride
concentrations were significantly lower in the premixed bags. These three electrolytes can be the
limiting component when prescribing a multi-chamber PN in some acute patients. Physicians from
our Nutrition Unit also prescribe this type of PN when it fits the patient needs, particularly the
macronutrient needs, and even aseptically add in the pharmacy vitamins, trace elements and
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electrolytes when the patient requires them. However, these results are not shown as this was not the
purpose of the study.
Our nutrition support team takes care of patients both in outpatient and inpatient settings. In the
latter, the nutrition support team conducts an assessment of nutritional status and gives individualized
nutritional treatment for patients under our care. The two main applicant services for our parenteral
nutrition services are General Surgery, which is not surprising in a tertiary referral hospital with many
daily complex surgeries, and Haematology, which has numerous stem cell transplantations each year.
Together with Haematology, we have recently developed a protocol of nutritional intervention to
cover the nutritional needs of their patients, who often must be carefully managed as they are critically
ill [30]. The suggestions of ESPEN seem to favour enteral tube feeding over PN, unless severe mucositis,
vomiting, diarrhoea, malabsorption, ileus or gastrointestinal graft-versus-host disease exists [12].
According to our experience, this symptomatology frequently appears in these transplantation patients
and thus, we generally start PN on the 2nd day post-transplantation [30].
5. Conclusions
To develop a high-quality and efficient clinical practice that is responsive to the current state of
knowledge, it is essential to perform an analysis of results.
The nutritional composition of parenteral nutrition formulae analysed in our study was chosen
based on the calculation of the nutritional requirements of each of our patients. This calculation follows
the protocols used in our hospital and is in line with the recommendations expressed by various
scientific organizations and our experience.
Our results allow us to affirm that we frequently ask our colleagues from the Pharmacy
department for PN preparations with a high content of nitrogen in relation to the amount of non-protein
calories, which also depends on the degree of metabolic stress of the patient. Using high-quality
fat preparations, we will match the amount of non-protein calories from glucose and fat with
the long-awaited best metabolic tolerance. Likewise, the individualization of the contribution of
micronutrients and volume to be infused is essential. This obviously requires daily monitoring of
the patient and continuous adjustment based on the clinical evaluation as it occurs in our clinical
practice. In any case, more studies in real clinical practice are needed to guide clinicians in their daily
clinical decisions.
Although the use of ready-to-use parenteral formulations is becoming increasingly common,
those who design the formulations will have to take the usual hospital practice into consideration as
well as the recommendations given by scientific organizations in their clinical practice guidelines.
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